Details of the Drug Combinations

General Information of This Drug (ID: DMKWCTR)

Drug Name

GS-9973 DMKWCTR

Synonyms

Entospletinib; 1229208-44-9; GS-9973; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; GS-9973; Entospletinib; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 2	[1]
B-cell lymphoma	2A86	Phase 2	[2]
Haematological malignancy	2B33.Y	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL is unavailable

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
GS-9973 + Panobinostat	DC7V6C4	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
------------------------------------------------------------------------------------

6 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
GS-4059 + GS-9973	DCX7QR1	GS-4059	B-cell Malignancies	[4]
GS-9973 + Daunorubicin	DCKKHBI	Daunorubicin	Hematologic Malignancy	[5]
GS-9973 + Daunorubicin	DCKP0X6	Daunorubicin	Acute Myeloid Leukemia	[6]
GS-9973 + Decitabine	DCRCOBS	Decitabine	Acute Myeloid Leukemia	[6]
Idelalisib + GS-9973	DCFV208	Idelalisib	Chronic Lymphocytic Leukemia	[7]
Vincristine + GS-9973	DCPLEEH	Vincristine	Non-Hodgkin Lymphoma	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 DrugCom(s)

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7889).
3	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
4	ClinicalTrials.gov (NCT02457598) Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies
5	ClinicalTrials.gov (NCT03135028) Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults
6	ClinicalTrials.gov (NCT02343939) Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
7	ClinicalTrials.gov (NCT01796470) Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
8	ClinicalTrials.gov (NCT02568683) Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)